Drug binding and drug-drug interaction considerations in individuals with obesity before and after bariatric surgery: A retrospective cross-sectional study

Moura, Emerita Quintina de Andrade; Siqueira, Carolina Dumke de; Martins, Ana Carolina; Nunes, Bruno Fonseca; Moraes, Ana Carolina Rabello de; Filippin-Monteiro, Fabíola Branco

doi:10.1016/j.medidd.2023.100152

Cited by 1 publication

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Across the literature, protein binding is consistently reported as a factor that potentially changes the pharmacokinetics of a drug in patients who are obese 8,10–13,26–29 . A decrease in the concentrations of plasma proteins in a subject with obesity would impact the flow of drugs into tissue compartments and, overall, the concentrations of free drugs in the plasma.…”

Section: Decision Tree Framework To Inform On Drugs That Are Expected...mentioning

confidence: 99%

Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework

Langevin,

Gobburu,

Gopalakrishnan

2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Obesity is a growing global health concern associated with high comorbidity rates, leading to an increasing number of patients who are obese requiring medication. However, clinical trials often exclude or under‐represent individuals who are obese, creating the need for a methodology to adjust labeling to ensure safe and effective dosing for all patients. To address this, we developed a 2‐part decision tree framework to prioritize drugs for dedicated pharmacokinetic studies in obese subjects. Leveraging current drug knowledge and modeling techniques, the decision tree system predicts expected exposure changes and recommends labeling strategies, allowing stakeholders to prioritize resources toward the drugs most in need. In a case study evaluating 30 drugs from literature across different therapeutic areas, our first decision tree predicted the expected direction of exposure change accurately in 73% of cases. We conclude that this decision tree system offers a valuable tool to advance research in obesity pharmacology and personalize drug development for patients who are obese, ensuring safe and effective medication.

show abstract

Section: Decision Tree Framework To Inform On Drugs That Are Expected...mentioning

confidence: 99%

Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework

Langevin,

Gobburu,

Gopalakrishnan

2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

Drug binding and drug-drug interaction considerations in individuals with obesity before and after bariatric surgery: A retrospective cross-sectional study

Cited by 1 publication

References 55 publications

Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework

Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework

Contact Info

Product

Resources

About